Browsing by Author "Gokdemir Y."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Geographical barriers to timely diagnosis of cystic fibrosis and anxiety level of parents during newborn screening in Turkey
    (John Wiley and Sons Inc, 2021) Gokdemir Y.; Eyuboglu T.S.; Emiralioglu N.; Er B.; Sen V.; Pekcan S.; Ergenekon A.P.; Hizal M.G.; Eryilmaz S.; Kose M.; Hangul M.; Cakir E.; Cokugras H.; Kılınc A.A.; Sasıhuseyinoglu A.S.; Altintas D.U.; Gulen F.; Eski A.; Bingol A.; Ozdemir A.; Topal E.; Gursoy T.R.; Girit S.; Ay P.; Yılmaz O.
    Background: Despite the availability of cystic fibrosis (CF) screening countrywide, diagnostic delay is still a crucial issue. The objectives of this study were to explore the stages of the NBS process, determine the risk factors associated with diagnostic delay and evaluate parent anxiety and experience throughout the process. Methods: This is a multicenter cross-sectional study. A questionnaire was completed by parents of newborns diagnosed with CF via NBS in 17 centers. Socio-demographic characteristics, parent knowledge and experiences related to NBS, sweat test availability in the region of residence, and time to the definitive CF diagnosis were assessed through this questionnaire. Parents' anxiety levels were evaluated through the State-Trait Anxiety Inventory scales 1 and 2. Delayed diagnosis (DD) was defined as a definite CF diagnosis beyond the 8th week of life. Predictors of delayed CF diagnosis were evaluated by univariate and multivariate analysis. Results: A total of 220 CF patients diagnosed via NBS were enrolled; 82 (37.3%) babies had DD. Multivariable analysis indicated that residence in the Southeast Anatolia region of Turkey (OR = 10.79, 95% CI = 2.37–49.2) was associated with a higher incidence of DD compared with other regions in Turkey. Of the total, 216 (98.1%) of the caregivers regarded the NBS program as useful and 180 (82%) reported high anxiety levels. Conclusion: The organization of newborn screening should take into account regional and socio-cultural characteristics to improve the early diagnosis of CF and also reduce the anxiety level of parents. © 2021 Wiley Periodicals LLC
  • No Thumbnail Available
    Item
    Epidemiological, Clinical, and Laboratory Features of Children With COVID-19 in Turkey
    (Frontiers Media S.A., 2021) Karbuz A.; Akkoc G.; Bedir Demirdag T.; Yilmaz Ciftdogan D.; Ozer A.; Cakir D.; Hancerli Torun S.; Kepenekli E.; Erat T.; Dalgic N.; Ilbay S.; Karaaslan A.; Erdeniz E.H.; Aygun F.D.; Bozdemir S.E.; Hatipoglu N.; Emiroglu M.; Sahbudak Bal Z.; Ciftci E.; Bayhan G.I.; Gayretli Aydin Z.G.; Ocal Demir S.; Kilic O.; Hacimustafaoglu M.; Sener Okur D.; Sen S.; Yahsi A.; Akturk H.; Cetin B.; Sutcu M.; Kara M.; Uygun H.; Tural Kara T.; Korukluoglu G.; Akgun O.; Üstündağ G.; Demir Mis M.; Sali E.; Kaba O.; Yakut N.; Kılıc O.; Kanik M.K.; Cetin C.; Dursun A.; Cicek M.; Kockuzu E.; Sevketoglu E.; Alkan G.; Guner Ozenen G.; İnce E.; Baydar Z.; Ozkaya A.K.; Ovali H.F.; Tekeli S.; Celebi S.; Cubukcu B.; Bal A.; Khalilova F.; Kose M.; Hatipoglu H.U.; Dalkiran T.; Turgut M.; Basak Altas A.; Selcuk Duru H.N.; Aksay A.; Saglam S.; Sari Yanartas M.; Ergenc Z.; Akin Y.; Duzenli Kar Y.; Sahin S.; Tuteroz S.K.; Bilen N.M.; Ozdemir H.; Senoglu M.C.; Pariltan Kucukalioglu B.; Besli G.E.; Kara Y.; Turan C.; Selbest Demirtas B.; Celikyurt A.; Cosgun Y.; Elevli M.; Sahin A.; Bahtiyar Oguz S.; Somer A.; Karadag B.; Demirhan R.; Turk Dagi H.; Kurugol Z.; Taskin E.C.; Sahiner A.; Yesil E.; Ekemen Keles Y.; Sarikaya R.; Erdem Eralp E.; Ozkinay F.; Konca H.K.; Yilmaz S.; Gokdemir Y.; Arga G.; Ozen S.; Coksuer F.; Vatansever G.; Tezer H.; Kara A.
    Objectives: The aim of this study is to identify the epidemiological, clinical, and laboratory features of coronavirus disease 2019 (COVID-19) in children. Methods: A retrospective study was conducted by pediatric infectious disease specialists from 32 different hospitals from all over Turkey by case record forms. Pediatric cases who were diagnosed as COVID-19 between March 16, 2020, and June 15, 2020 were included. Case characteristics including age, sex, dates of disease onset and diagnosis, family, and contact information were recorded. Clinical data, including the duration and severity of symptoms, were also collected. Laboratory parameters like biochemical tests and complete blood count, chest X-ray, and chest computed tomography (CT) were determined. Results: There were 1,156 confirmed pediatric COVID-19 cases. In total, male cases constituted 50.3% (n = 582) and females constituted 49.7% (n = 574). The median age of the confirmed cases was 10.75 years (4.5–14.6). Of the total cases, 90 were younger than 1 year of age (7.8%), 108 were 1–3 years of age (9.3%), 148 were 3–6 years of age (12.8%), 298 were 6–12 years of age (25.8%), 233 were 12–15 years of age (20.2%), and 268 cases were older than 15 years of age (23.2%). The most common symptom of the patients at the first visit was fever (50.4%) (n = 583) for a median of 2 days (IQR: 1–3 days). Fever was median at 38.4°C (38.0–38.7°C). The second most common symptom was cough (n = 543, 46.9%). The other common symptoms were sore throat (n = 143, 12.4%), myalgia (n = 141, 12.2%), dyspnea (n = 118, 10.2%), diarrhea (n = 112, 9.7%), stomachache (n = 71, 6.1%), and nasal discharge (n = 63, 5.4%). When patients were classified according to disease severity, 263 (22.7%) patients were asymptomatic, 668 (57.7%) patients had mild disease, 209 (18.1%) had moderate disease, and 16 (1.5%) cases had severe disease. One hundred and forty-nine (12.9%) cases had underlying diseases among the total cases; 56% of the patients who had severe disease had an underlying condition (p < 0.01). The need for hospitalization did not differ between patients who had an underlying condition and those who do not have (p = 0.38), but the need for intensive care was higher in patients who had an underlying condition (p < 0.01). Forty-seven (31.5%) of the cases having underlying conditions had asthma or lung disease (38 of them had asthma). Conclusions: To the best of our knowledge, this is one of the largest pediatric data about confirmed COVID-19 cases. Children from all ages appear to be susceptible to COVID-19, and there is a significant difference in symptomatology and laboratory findings by means of age distribution. © Copyright © 2021 Karbuz.
  • No Thumbnail Available
    Item
    Childhood interstitial lung disease survivors in adulthood: a European collaborative study
    (2025) Manali E.D.; Griese M.; Nathan N.; Uzunhan Y.; Borie R.; Michel K.; Schwerk N.; Fijolek J.; Radzikowska E.; Chua F.; Pabary R.; Mogulkoc N.; McCarthy C.; Kallieri M.; Papaioannou A.I.; Kiper N.; Koziar Vasakova M.; Lacina L.; Molina-Molina M.; Torrent-Vernetta A.; Tsiligiannis T.; Karadag B.; Kokosi M.; Renzoni E.A.; van Moorsel C.H.M.; Campo I.; Bendstrup E.; Prior T.S.; Prasse A.; Bonella F.; Cottin V.; Diesler R.; Froidure A.; Kolilekas L.; Fotis L.; Douros K.; Kaditis A.G.; Jeny F.; Chauveau S.; Nunes H.; Dahbia A.; Mariani F.; van der Vis J.J.; Groen K.; Erdem Eralp E.; Gokdemir Y.; Kocakaya D.; Olgun Yildizeli S.; Yalçın E.; Emiralioğlu N.; Nayir Buyuksahin H.; O'Brien H.; Karcıoglu O.; Can D.; Ezircan A.; Kartal Ozturk G.; Ocal N.; Yuksel H.; Narin Tongal S.; Safrankova M.; Kourtesi K.; Louvrier C.; Kannengiesser C.; Fabre A.; Legendre M.; Crestani B.; Pohunek P.; Bush A.; Papiris S.A.
    BACKGROUND: Interstitial lung disease is rarer in children than adults, but, with increasing diagnostic awareness, more cases are being discovered. The prognosis of childhood interstitial lung disease is often poor, but increasing numbers are now surviving into adulthood. AIM: To characterise childhood interstitial lung disease survivors and identify their impact on adult interstitial lung disease centres. METHODS: This was a European study (34 adult and childhood interstitial lung disease centres) reporting incident/prevalent cases of childhood interstitial lung disease survivors from January to July 2023. Epidemiological, clinical, physiological and genetic data were collected. RESULTS: 244 patients were identified with a median (interquartile range) age at diagnosis of 12.5 years (6-16 years) and age at study inclusion of 25 years (22-33 years), with 51% male, 86% nonsmokers and a median (interquartile range) % predicted forced vital capacity of 70% (47-89%) and diffusing capacity of the lungs for carbon monoxide of 48% (32-75%). 32% were prescribed long-term oxygen and 227 (93%) were followed up in adult centres whereas 17 (7%) never transitioned. The commonest diagnoses (82%) were childhood interstitial lung disease category B1 (sarcoidosis, hemosiderosis, connective tissue disorders, vasculitis) at 35%, A4 (surfactant-related) at 21%, B2 (bronchiolitis obliterans, hypersensitivity pneumonitis) at 14% and Bz (unclassified interstitial lung disease) at 13%. Bz patients had the worst functional status. 60% of all patients were still being prescribed corticosteroids. Re-specification of diagnosis and treatment were made after transition for 9.8% and 16% of patients, respectively. Not all childhood interstitial lung disease diagnoses were recognised in adult interstitial lung disease classifications. CONCLUSION: Childhood interstitial lung disease survivors are seen in most adult interstitial lung disease centres and only a minority continue follow-up in paediatric centres. Survivors have a significant loss of lung function. The heterogeneity of their aetiologies and therapeutic requirements has a real impact on adult interstitial lung disease centres. Re-specification of diagnosis and treatment may contribute to precision and personalisation of management. Copyright ©The authors 2025. For reproduction rights and permissions contact permissions@ersnet.org.